Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

View All Documentation

Y0000557

Fluconazole

European Pharmacopoeia (EP) Reference Standard

Szinonimák:

2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)

About This Item

Tapasztalati képlet (Hill-képlet):
C13H12F2N6O
CAS-szám:
86386-73-4
Molekulatömeg:
306.27
MDL-szám:
MFCD00274549
UNSPSC kód:
41116107
PubChem Substance ID:
329831019
NACRES:
NA.24

grade

pharmaceutical primary standard

API-család

fluconazole

gyártó/kereskedő neve

EDQM

alkalmazás(ok)

pharmaceutical (small molecule)

format

neat

tárolási hőmérséklet

2-8°C

SMILES string

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

Nemzetközi kémiai azonosító kulcs

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Looking for similar products? Látogasson el ide Útmutató a termékösszehasonlításhoz

Related Categories

Általános leírás

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Alkalmazás

Fluconazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biokémiai/fiziológiai hatások

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.

Kiszerelés

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Egyéb megjegyzések

Sales restrictions may apply.

kapcsolódó termék

Product No.
Leírás
Árazás

1271700

Fluconazole, United States Pharmacopeia (USP) Reference Standard

Y0000558

Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000574

Fluconazole impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000573

Fluconazole impurity B, European Pharmacopoeia (EP) Reference Standard

1271733

Fluconazole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1271722

Fluconazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1271711

Fluconazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1651

Fluconazole Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1826

Fluconazole Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1862

Fluconazole Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2037

Fluconazole Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

BP1174

Fluconazole, British Pharmacopoeia (BP) Reference Standard

BP1175

Fluconazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2048

Fluconazole Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2046

Fluconazole Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1900

Fluconazole Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9026

1,2,4-Triazole, reference material

PHR9031

2-(2,4-Difluorophenyl)-1,2,3-propanetriol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Piktogramok

Health hazardExclamation mark
GHS08,GHS07

Figyelmeztetés

Danger

Figyelmeztető mondatok

H302,H360D,H362,H412

Óvintézkedésre vonatkozó mondatok

P202 - P260 - P263 - P273 - P301 + P312 - P308 + P313

Veszélyességi osztályok

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

Tárolási osztály kódja

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.

Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

A-C L Meyer et al.
Tropical medicine & international health : TM & IH, 18(4), 495-503 (2013-02-02)
To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated
M A Pfaller et al.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 13(6), 180-195 (2010-11-06)
Both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have MIC clinical breakpoints (CBPs) for fluconazole (FLU) and Candida. EUCAST CBPs are species-specific, and apply only to C. albicans, C. tropicalis and
Mahipal Sinnollareddy et al.
Expert opinion on drug metabolism & toxicology, 7(11), 1431-1440 (2011-09-03)
Invasive candidiasis has emerged over the last few decades as an increasingly important nosocomial problem for the critically ill, affecting around 2% of intensive care unit patients. Although poor outcomes associated with invasive candidiasis among critically ill patients may relate
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
View All Related Papers

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással